2015 ACG ANNUAL SCIENTIFIC MEETING
Symposia Sessions, Special Lectures and Oral Abstract Presentations

Program Description, Faculty Listing and Disclosure Information ......................... viii
Course Evaluation and CME Information ................................................................. xvii

MONDAY MORNING, October 19, 2015
10:25 am–11:40 am Simultaneous Symposia 1

Simultaneous Symposia 1A: Hepatitis C Update
Moderator: Stanley M. Cohen, MD

New Guideline-based Treatment
Nancy S. Reau, MD .............................................................. 1
Identify appropriate treatment regimens for specific hepatitis C populations.

The Approach to the Treatment of the Complicated Hepatitis C Patient
Paul Martin, MD, FACG .................................................. 7
Evaluate and successfully manage patients with decompensated cirrhosis, renal failure and coinfection.

Navigating Hepatitis C Treatment in My Practice
Stanley M. Cohen, MD ........................................................... 14
Apply practical approaches to prior authorization, compliance and side effect management.

Simultaneous Symposia 1B: Colonoscopy Quality in Practice: Fewer Mulligans, Next Steps After Failing to Make Par and Comparing Handicaps
Moderator: David M. Kastenberg, MD, FACG

Improving Prep: Fewer Mulligans
David M. Kastenberg, MD, FACG .......................................... 21
Describe grading systems for colonic preparations and identify practical strategies to optimize outcomes.

Incomplete Colonoscopy: Next Steps After Failing to Make Par
Joseph G. Cheatham, MD .................................................. 28
Compare and contrast alternate methods after technical failure of optical colonoscopy.

How Do I Stack Up Against My Peers and Why Does This Matter? Comparing Handicaps
David A. Johnson, MD, MACG ........................................... 32
Summarize the implications of individual reporting of colonoscopy quality metrics and strategies to improve the metrics.

MONDAY AFTERNOON, October 19, 2015
1:25 pm–2:10 pm

The American Journal of Gastroenterology Lecture
How Information Technology Will Transform Gastroenterology
Brennan M. R. Spiegel, MD, MSHS, FACG .............................................. 36
Evaluate the impact that new technological innovations will have on patient care.

Please note: While evaluations for CME credit can ONLY be completed online (at www.evals.gi.org/am/2015), information corresponding to the online evaluation is provided on page xvii to assist you in evaluating this course.
2:55 pm–4:10 pm  Simultaneous Symposia 2

Simultaneous Symposia 2A: Preventing Problems and Treating Them as They Arise
Moderator: Girish Mishra, MD, MSc, FACC

Preventing Post-ERCP Pancreatitis
Martin L. Freeman, MD, FACC ................................................................. 50
Apply evidence-based strategies to reduce post-ERCP pancreatitis via patient selection, endoscopic technique and pharmacologic intervention.

Managing the Complications of Acute Pancreatitis: From Necrosis to Thrombosis
Peter V. Draganov, MD, FACC ....................................................... 58
Manage challenging complications of acute pancreatitis.

Killing the Pain (But Not the Patient) in Chronic Pancreatitis
Girish Mishra, MD, MSc, FACC ......................................................... 63
Compare treatment methods for painful chronic pancreatitis.

Simultaneous Symposia 2B: Inflammatory Bowel Disease Therapy: Making the Most of What We Have
Moderator: William J. Tremaine, MD, FACC

Corticosteroids and Thiopurines: Still Relevant to IBD in 2015?
William J. Tremaine, MD, FACC ........................................................... 69
Justify the use of corticosteroids and thiopurines in the era of biologics.

Good to the Last Drop: Optimizing Biologic Therapy in IBD
Fernando S. Velayos, MD, MPH .......................................................... 73
Calculate appropriate dosing regimens for biologic therapy.

Generic Anti-tumor Necrosis Factor Therapy: Biosimilars – Saints or Sinners?
Gary R. Lichtenstein, MD, FACC .......................................................... 81
Assess the impact of biosimilars on treatment regimens.

Simultaneous Symposia 2C: Live from Honolulu! The 3rd Annual Endoscopy Video Forum
Moderator: Seth A. Gross, MD, FACC
Judges: Douglas G. Adler, MD, FACC, Carol A. Burke, MD, FACC, John R. Saltzman, MD, FACC, and Michael B. Wallace, MD, MPH, FACC

See page v for listing information

TUESDAY MORNING, October 20, 2015

8:30 am–9:00 am

J. Edward Berk Distinguished Lecture
Sleep Effect on GI Health and Disease: Eyes Wide Open?
David A. Johnson, MD, MACG ......................................................... 87
Interpret the data on sleep effects on gastrointestinal health and disease.

9:45 am–11:00 am  Simultaneous Symposia 3

Simultaneous Symposia 3A: Evolving Concepts in the Treatment of IBS
Moderator: William D. Chey, MD, FACC

Probiotics and Antibiotics: Are These First-Line Agents?
Mark Pimentel, MD, FACC ............................................................... 95
Evaluate the clinical efficacy and safety of probiotics and antibiotics in IBS patients.

Diet: Which Should You Choose for Your IBS Patient?
William D. Chey, MD, FACC .............................................................. 102
Assess dietary interventions in IBS using an evidence-based approach.
When Your Patient Wants a Pill: What Are the New and Upcoming Pharmacologic Options?
Darren M. Brenner, MD .......................................................... 107
Outline new treatments for IBS (eluxadoline, plecanatide, elobixibat, linaclotide) and upcoming therapies.

Simultaneous Symposia 3B: The PPI Non-responsive Patient
Moderator: John E. Pandolfino, MD, MSCI, FACG

The Unresponsive and the Refractory Patient: What to Do and How to Manage
John E. Pandolfino, MD, MSCI, FACG ............................................ 112
Use diagnostic tools to differentiate the unresponsive from the truly refractory GERD patient and outline the therapeutic options for these patients.

The Functional GERD Patient (Visceral Hypersensitivity): Treatment Options
Ronnie Fass, MD, FACG .......................................................... 117
Assess the diagnostic criteria of functional GERD and visceral hypersensitivity and implement appropriate evidence-based medicine treatments.

Diagnosis and Management of the Non-acid Reflux Patient
Marcelo F. Vela, MD, MSCR, FACG ................................................ 124
Define the role of pH-impedance testing and the criteria for ineffective peristalsis and, identify the most appropriate treatments available for these conditions.

TUESDAY AFTERNOON, October 20, 2015

2:15 pm–2:45 pm
Emily Couric Memorial Lecture
National Registry Benchmarking for Colonoscopy Quality: The “High Road” Toward Improving the Performance of Colonoscopy and Cancer Prevention
Irving M. Pike, MD, FACG ........................................................ 129
Appreciate the impact of measuring performance on improving GI endoscopic quality.

2:45 pm–4:00 pm  Simultaneous Symposia 4

Simultaneous Symposia 4A: The Sick Liver: Management of the Complications of Decompensated Cirrhosis
Moderator: Mark W. Russo, MD, MPH, FACG

The Bleeding Won’t Stop: Portal Hypertensive Bleeding
Mark W. Russo, MD, MPH, FACG .................................................. 134
Summarize appropriate management of portal hypertensive bleeding.

I’m Still Confused: Management of Hepatic Encephalopathy Beyond Lactulose
Jasmohan S. Bajaj, MD, MSc, FACG .............................................. 139
Apply medical and dietary treatment alternatives to the patient who has encephalopathy and is not responding to lactulose.

Cancer in the Liver: The Next Step
Joseph Ahn, MD, MS, FACG ..................................................... 145
Evaluate the multidisciplinary management of hepatocellular carcinoma.

Simultaneous Symposia 4B: Controversies in the Management of Inflammatory Bowel Disease: Case Studies
Moderator: Uma Mahadevan, MD, FACG

The Use of Biologics as First-Line Therapy in the Treatment of IBD: One Size Fits All?
Bruce E. Sands, MD, MS, FACG ................................................. 150
Select the appropriate patient to use biologic therapy as the first-line agent.
Doctor, Do I Have to Take This Medication Forever? Escalation and De-escalation of Therapy in IBD
Uma Mahadevan, MD, FACP .......................................................... 156
Assess how to alter dosing based on patient response.

Continuing Immunosuppressive Therapy in the Patient With Infection or Malignancy
Edward V. Loftus, Jr., MD, FACP .................................................. 160
Evaluate the risk of therapy in the setting of relative contraindications.

Simultaneous Symposia 4C: CRE Infections in Endoscopy: What Happened and What Now?
Moderator: David A. Greenwald, MD, FACP

Duodenoscope Infections With CRE: What Happened?
David A. Greenwald, MD, FACP
Discuss duodenoscope infections with CRE.

Infection Control and Safety In Endoscopy: Guidelines and Standards
John A. Martin, MD
Describe infection control and safety in endoscopy.

CRE Related Infections in Endoscopy: What To Do Now?
Douglas G. Adler, MD, FACP
Identify ways to prevent CRE related infections in endoscopy.

WEDNESDAY MORNING, October 21, 2015

8:45 am–9:15 am
David Y. Graham Lecture
Eosinophilic Esophagitis 2015: From Acid Reflux to Food Allergy
Ikuo Hirano, MD, FACP .......................................................... 163
Recognize the importance of dietary factors in the pathogenesis and treatment of eosinophilic esophagitis.

9:30 am–10:45 am   Simultaneous Symposia 5

Simultaneous Symposia 5A: Screening and Surveillance: Challenging Cases
Apply the best evidence to common clinical conundrums in an interactive case-based discussion forum.
Panelist: Aasma Shaukat, MD, MPH, FACP ..................................... 171
Panelist: Carol A. Burke, MD, FACP ........................................... 176
Panelist: Jason A. Dominitz, MD, MHS ......................................... 181

Simultaneous Symposia 5B: Endoscopic Ablation of Barrett’s: How Far Have We Come?
Moderator: Nicholas J. Shaheen, MD, MPH, FACP

Ablation Therapies of Barrett’s: To Freeze or to Burn the Dysplastic Barrett’s Esophagus Patient and Its Role in Early Adenocarcinoma
Nicholas J. Shaheen, MD, MPH, FACP ......................................... 188
Identify the benefits and limitations of RFA and cryotherapy for dysplastic Barrett’s metaplasia and summarize surveillance protocols after eradication.

When Is It Appropriate to Recommend Ablation for Non-Dysplastic Barrett’s?
Peter J. Kahrilas, MD, FACP ..................................................... 194
Analyze the adverse outcomes, risks and benefits of ablation therapy in patients with low risk and non-dysplastic Barrett’s metaplasia.

Risk and Treatment of Persistent and Recurrent Barrett’s Metaplasia: When to Stop and What to Do With the “Buried Glands”
Kenneth K. Wang, MD, FACP .................................................. 199
Explain the approach to treat the dysplastic Barrett’s esophagus and the practical endpoints with emphasis on persistent, recurrent Barrett’s after ablation and buried glands.
## ORAL ABSTRACT PRESENTATIONS

### Monday, October 19, 2015

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Diabetes Mellitus and Metabolic Syndrome: Independent Risk Factors for Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>2.</td>
<td>Prognostic Impact of Achieving Sustained Viral Response in Patients With Hepatitis C After Curative Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis</td>
</tr>
<tr>
<td>3.</td>
<td>Rate, Risk Factors, and Outcomes of de novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis</td>
</tr>
<tr>
<td>4.</td>
<td>Gut Microbiota Changes as Predictors of Treatment Failure in Primary <em>Clostridium difficile</em> Infection</td>
</tr>
<tr>
<td>5.</td>
<td>Associations of Clinical Symptoms and Bowel Characteristics With Intestinal Microbiota in Patients With Irritable Bowel Syndrome</td>
</tr>
<tr>
<td>6.</td>
<td>Impact of Histology Confirmation by GI Pathologist Panel on Progression Rates in Barrett’s Esophagus With Low-Grade Dysplasia: Results From a Multicenter Prospective BE Registry</td>
</tr>
<tr>
<td>7.</td>
<td>Does Obesity Impact Mortality and Other Outcomes in Patients With Upper Gastrointestinal Hemorrhage? A Nationwide Analysis</td>
</tr>
<tr>
<td>8.</td>
<td>The Comparative Effectiveness of Upper Endoscopy and Angiographic Embolization in Achieving Hemostasis for Recurrent Non-Variceal Upper Gastrointestinal Bleeding</td>
</tr>
<tr>
<td>9.</td>
<td>Pancreatic Cancer in Urban African Americans: Too Young, Too Late!</td>
</tr>
<tr>
<td>10.</td>
<td>Effect of an Endoscopic Quality Improvement Program on Adenoma Detection Rates: A Multicenter Cluster-Randomized Controlled Trial in Clinical Practice Setting (EQUIP-3)</td>
</tr>
<tr>
<td>11.</td>
<td>Etiologies and Clinical Features of Nonresponsive Celiac Disease in Children Under the Age of 18 Years</td>
</tr>
<tr>
<td>12.</td>
<td>Endoscopic Evaluation and Associations With Clinical Manifestations of Acute Gastrointestinal Graft-versus-Host Disease</td>
</tr>
<tr>
<td>13.</td>
<td>Association of Aortic Valve Disease Associated With Bleeding Arteriovenous Malformations of the Gastrointestinal Tract: Data From the Nationwide Inpatient Sample</td>
</tr>
<tr>
<td>14.</td>
<td>Gastrointestinal Bleeding Among Mechanical Circulatory Support Devices Recipients: A Nationwide Perspective</td>
</tr>
<tr>
<td>15.</td>
<td>Gastric Intestinal Metaplasia in a U.S. Tertiary Care Population</td>
</tr>
<tr>
<td>16.</td>
<td>Gastric Cancer Detection by Novel Methylated DNA Markers: Tissue Validation in Patient Cohorts From the United States and South Korea</td>
</tr>
<tr>
<td>17.</td>
<td>The Diagnostic Performance of FDG PET/CT for Recurrent Gastric Cancer Is Significantly Affected by Primary Tumor FDG Uptake Level</td>
</tr>
<tr>
<td>18.</td>
<td>No Paper #18</td>
</tr>
</tbody>
</table>

### Videos

- **Video 1.** Endoscopic Removal of Gastric Band Using Stent-Induced Erosion Technique
- **Video 2.** Large Gastric Conduit Dehiscence With Empyema Treated With Endoscopic Intervention
- **Video 3.** “GIST” Cut It out Already! Successful Removal of an Exophytic GIST in the Gastric Cardia via Endoscopic Full Thickness Resection
- **Video 4.** Endoscopic Closure of Gastric Defects Resulting From Endoscopic Full-thickness Resection by Application of Novel Endoloops and Metallic Clips, Using Single-channel Endoscope: A Multicenter Study
- **Video 5.** Endoscopic Management of a Gastrocolonic Fistula: A Rare Esophageal Stent Adverse Event
- **Video 6.** Endoscopic Needle-knife Strictureotomy in a UC Patient With Diverted Ileal Pouch and Anastomotic Stricture
- **Video 7.** Underwater Resection of Colorectal Neoplasia: Taking the Plunge Into a New Technique
- **Video 8.** A NOTES Approach to Acute Duodenal Perforation: A Minimally Invasive Approach Made Possible by an Effective Endoscopic Suturing System
- **Video 9.** Transrectal Pure NOTES Cholecystolithotomy and Gallbladder Polypectomy With Gallbladder Preserved: The First Report on Human Cases
19. A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study

20. First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in Ulcerative Colitis: A Post-hoc Analysis of a Multicenter Prospective Randomized Controlled Trial

21. Efficacy of Vedolizumab Maintenance Therapy With and Without Continued Immunosuppressant Use in GEMINI 1 and GEMINI 2

22. Fecal Calprotectin Levels Can Predict Pharmacokinetics of Anti-TNF Therapy

23. Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn’s Disease

24. Angiotensin II Blockade Is Associated With Worse Clinical Outcomes in IBD Patients

25. Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients With Inflammatory Bowel Disease

26. Visceral Transplantation for End Stage Crohn’s Disease: 25 Years of Experience at a Single Center

27. Temporary Fecal Diversion for Colonic and/or Perianal Crohn’s Disease

28. Does Active Technician Involvement During a Screening Colonoscopy Improve Physician Adenoma Detection Rate?

29. Small Sessile Serrated Polyps Have Higher Rates of Advanced Adenomas Upon Surveillance Than Small Tubular Adenomas

30. Screening Colonoscopy Withdrawal Time and Proximal Serrated Polyp Detection Rate: Analysis of a Large, Single, High-Volume Center Using Natural Language Processing

31. G-EYE™, High-Definition Colonoscopy Increases Adenoma Detection Rate Compared to Standard High Definition Colonoscopy: Results of Prospective Randomized Multicenter Trial

32. Colorectal Cancer: Clinical Differences Among Hispanics and Non-Hispanic Whites: A Single Institution’s Experience Over 20 Years

33. Downregulation of Novel Tumor Suppressor Gene SA-1 in Early Colon Carcinogenesis Has a Predilection for Blacks: Potential Biological Underpinnings for Colorectal Cancer (CRC) Disparities

34. Higher Rates of Advanced Histology in Small Adenomas Found on Surveillance After Colorectal Cancer Resection Compared to Average-Risk Screening

35. No Paper #35

36. No Paper #36

37. Can the Use of Mesalamine Prevent Recurrent Diverticulitis? A Meta-analysis of Randomized Controlled Trials

38. The Cost-Effectiveness of Competing Strategies for Managing Multiply Recurrent *Clostridium difficile* Infection: Examining the Impact of Universal Stool Banks and Encapsulated Fecal Microbiota Transplantation

39. Predictors of Failure After Fecal Microbiota Transplantation (FMT) for the Therapy of *Clostridium difficile* Infection (CDI)

40. Association of Chronic Constipation With Gastrointestinal Complications in Younger Patients

41. Clinical Success of Colonic Stenting in Patients With Malignant Large Bowel Obstruction Due to Extracolonic Malignancy

42. Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

43. Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of Exhaled Methane: A Large-scale Database Analysis

44. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Recurrent *Clostridium difficile* Infection

45. No Paper #45

46. Impact of Recent Guidelines on the Role of EUS in Diagnosis of Asymptomatic Neoplastic Pancreatic Cysts

47. Analytic Morphomics Accurately Distinguishes Serous and Mucinous Cystic Neoplasms
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Utility of MicroRNAs in Differentiating Pancreatic Cancer and Autoimmune Pancreatitis</td>
<td>255</td>
</tr>
<tr>
<td>49</td>
<td>Cost Effectiveness and Clinical Efficacy of Plastic vs Self-Expandable Metal Stents for Management of Biliary Obstruction Due to Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy</td>
<td>256</td>
</tr>
<tr>
<td>50</td>
<td>Has Survival Improved Following Resection for Pancreatic Adenocarcinoma?</td>
<td>257</td>
</tr>
<tr>
<td>51</td>
<td>Detection of Crohn’s Disease in Patients With Spondyloarthropathies (SpA): A Prospective Capsule Endoscopy-Based Study (SpACE Capsule Study)</td>
<td>257</td>
</tr>
<tr>
<td>52</td>
<td>Potential Risks of Immunosuppressant Drugs to the Pregnant Patient</td>
<td>258</td>
</tr>
<tr>
<td>53</td>
<td>Colorectal Surgery in Inflammatory Bowel Disease (IBD)-Associated Colorectal Cancer (CRC) Patients Has Worse Health Outcomes Than in Non-IBD Associated CRC Patients</td>
<td>258</td>
</tr>
<tr>
<td>54</td>
<td>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Ustekinumab, a Human Monoclonal Antibody to IL-12/23P40, in Patients With Moderately- to Severely-Active Crohn’s Disease Who Are Naive or not Refractory to Anti-TNFα: Results From the UNITI-2 Study</td>
<td>260</td>
</tr>
</tbody>
</table>

**Wednesday, October 21, 2015**

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Transepithelial Brush Biopsies With Computer-Assisted 3-Dimensional Analysis Markedly Improve Detection of Barrett’s Esophagus and Dysplasia: Interim Analysis From a Prospective Multi-Center Community-Based Study</td>
<td>261</td>
</tr>
<tr>
<td>56</td>
<td>Low Bleeding Rates Associated With Esophageal Endoscopic Mucosal Resection for the Treatment of Dysplastic Barrett’s Esophagus</td>
<td>262</td>
</tr>
<tr>
<td>57</td>
<td>2-Octyl-Cyanoacrylate Injection for Acute Gastric Variceal Hemorrhage: 15-Year Experience of Outcomes and Predictors of Acute Rebleeding</td>
<td>263</td>
</tr>
<tr>
<td>58</td>
<td>IW-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Symptoms of Refractory GERD in a Double-blind, Placebo-controlled Phase 2a Study</td>
<td>263</td>
</tr>
<tr>
<td>59</td>
<td>Esophagogastric Junction Contractile Integral (EGJ-CI) Quantifies Changes in EGJ Barrier Function With Surgical Intervention</td>
<td>265</td>
</tr>
<tr>
<td>60</td>
<td>Assessment of Post-treatment Outcomes in Achalasia Utilizing Novel, High-Resolution Impedance Manometry Parameters</td>
<td>266</td>
</tr>
<tr>
<td>61</td>
<td>Endoscopic Submucosal Tunnel Dissection for Upper GI Submucosal Tumors Originating From the Muscularis Propria Layer: A Prospective Study</td>
<td>267</td>
</tr>
<tr>
<td>62</td>
<td>EUS Is Not Required for Staging Newly Diagnosed Malignant Esophageal Strictures That Preclude the Passage of a Standard Gastroscope: Results of a Prospective, Multicenter Study</td>
<td>271</td>
</tr>
<tr>
<td>63</td>
<td>Changing PPI Prescribing Patterns in the Wake of Recently Reported Adverse Effects: A Survey Study Comparing Gastroenterologists and General Practitioners</td>
<td>271</td>
</tr>
<tr>
<td>64</td>
<td>Discordant Liver Histology and NAFLD Fibrosis Scores in Morbidly Obese Bariatric Surgery Subjects</td>
<td>272</td>
</tr>
<tr>
<td>65</td>
<td>High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r+Dasabuvir±Ribavirin: Integrated Safety and Efficacy Analysis</td>
<td>273</td>
</tr>
<tr>
<td>66</td>
<td>Acute Kidney Injury Among Hospitalized Patients With Alcoholic Liver Disease and Acute or Chronic Liver Failure</td>
<td>275</td>
</tr>
<tr>
<td>67</td>
<td>Sofosbuvir-Based Treatment Is Safe and Effective in Patients With Chronic Hepatitis C Infection and End-Stage Renal Disease</td>
<td>275</td>
</tr>
<tr>
<td>68</td>
<td>A Controlled Study of the Long-term Impact on Renal Function of Entecavir and Tenofovir Treatment for Chronic Hepatitis B</td>
<td>276</td>
</tr>
<tr>
<td>69</td>
<td>Does Cesarean Section and Formula Feeding Reduce Vertical Transmission in Chronic Hepatitis B Pregnant Mothers?</td>
<td>277</td>
</tr>
<tr>
<td>70</td>
<td>Early Use of TIPS and Outcomes in Patients With Cirrhosis and Acute Esophageal Variceal Bleeding: Analysis of the U.S. Nationwide Inpatient Sample (NIS) Database, 2000-2010</td>
<td>278</td>
</tr>
<tr>
<td>71</td>
<td>The Utility of Repeat Diagnostic Paracentesis in the Management of Spontaneous Bacterial Peritonitis</td>
<td>279</td>
</tr>
</tbody>
</table>